keyword
MENU ▼
Read by QxMD icon Read
search

S-ICD

keyword
https://www.readbyqxmd.com/read/29327463/subcutaneous-implantable-cardioverter-defibrillator-s-icd-shocks-in-a-patient-with-a-left-ventricular-assist-device
#1
Harsimran Saini, Aditya Saini, Jeannine Leffler, Steven Eddy, Kenneth A Ellenbogen
No abstract text is available yet for this article.
January 11, 2018: Pacing and Clinical Electrophysiology: PACE
https://www.readbyqxmd.com/read/29317975/subcutaneous-implantable-cardioverter-defibrillators-implantation-without-defibrillation-threshold-testing-a-single-center-experience
#2
Bandar Al-Ghamdi, Azam Shafquat, Nadiah Alruwaili, Shisamma Emmanual, Mohamed Shoukri, Yaseen Mallawi
Background: Subcutaneous implantable cardioverter defibrillator (S-ICD) system has been proven to be an effective therapy for prevention of sudden cardiac death (SCD) in selected patients. Although the Shockless IMPLant Evaluation (SIMPLE) trial has shown that defibrillation threshold (DFT) testing is not necessary for transvenous ICD (TV-ICD) systems, it is still recommended for S-ICD systems. We aimed to study the efficacy and safety of S-ICD implantation without DFT in our Heart Center with the comparison of S-ICD patients' outcome to those with a single chamber TV-ICD without DFT in the same period...
December 2017: Cardiology Research
https://www.readbyqxmd.com/read/29285623/right-versus-left-parasternal-electrode-position-in-the-entirely-subcutaneous-icd
#3
Markus Bettin, Dirk Dechering, Gerrit Frommeyer, Robert Larbig, Andreas Löher, Florian Reinke, Julia Köbe, Lars Eckardt
OBJECTIVES: The subcutaneous implantable cardioverter defibrillator (S-ICD®) has been established as an alternative to conventional transvenous ICD for the prevention of sudden cardiac death. Initial studies have shown safety and efficacy of the system with a left parasternal (LP) electrode. However, several case studies reported a right parasternal (RP) position. The purpose of this study was to analyze shock efficacy and safety of an RP electrode position. METHODS: Between June 2010 and May 2016, 120 S-ICD® were implanted at our institution...
December 28, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29273233/eligibility-of-cardiac-resynchronization-therapy-patients-for-subcutaneous-implantable-cardioverter-defibrillators
#4
Ghassan Moubarak, Pierre Maison-Blanche, Olivier Thomas
The eligibility for subcutaneous implantable cardioverter-defibrillators (S-ICD) was assessed among patients already implanted with cardiac resynchronization therapy (CRT). We included 20 patients (15 men, age 73±10years, LVEF 35±10%). Seventeen (85%) patients were eligible for S-ICDs: 11 (55%) patients on only 1 vector and 6 (30%) patients on 2 or 3 vectors. Patients who were eligible on 2-3 vectors had narrower paced QRS than patients who were not eligible or were eligible on only one vector (133±18ms vs 167±17ms, p=0...
December 8, 2017: Journal of Electrocardiology
https://www.readbyqxmd.com/read/29225826/subcutaneous-defibrillator-implantation-as-a-bridge-until-left-ventricular-function-normalizes
#5
Antonio Bisignani, Silvana De Bonis, Giovanni San Pasquale, Laura Candreva, Cristina Franchin, Maurizio Malacrida, Giovanni Bisignani
Patients with reversible cardiac impairment may be, at least temporarily, at high risk of SCD and may go unprotected for considerable time. A less-invasive definitive or bridge solution is the implantation of a subcutaneous cardioverter-defibrillator (S-ICD). The less invasiveness of this procedure ensures easy removal of the system without exposing the patient to the risk of complications.
December 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/29221700/acute-and-long-term-results-after-contemporary-subcutaneous-implantable-cardioverter-defibrillator-implantation-a-single-center-experience
#6
Miguel A Arias, Marta Pachón, Finn Akerström, Alberto Puchol, Cristina Martín-Sierra, Luis Rodríguez-Padial
INTRODUCTION AND OBJECTIVES: The subcutaneous implantable cardioverter-defibrillator (S-ICD) has emerged as an alternative to the transvenous defibrillator. The incidence of complications is similar, with inappropriate shocks (IS) being more frequent than those occurring with contemporary programming of transvenous defibrillators. Several improvements have been implemented after the S-ICD was approved for use in Europe in 2009. This study reports the results of S-ICD use in a single center, whose experience began late, at the end of 2013...
December 5, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29146276/perioperative-management-of-oral-anticoagulation-in-patients-undergoing-implantation-of-subcutaneous-implantable-cardioverter-defibrillator
#7
Muhammad R Afzal, Divyesh Mehta, Christopher Evenson, Daniel Pinkhas, Auroa Badin, Dilesh Patel, Michael K Essandoh, Hemant Godara, Jaret Tyler, Mahmoud Houmsse, Zhenguo Liu, Steven J Kalbfleisch, John D Hummel, Ralph Augostini, Raul Weiss, Emile G Daoud, Toshimasa Okabe
BACKGROUND: The perioperative anticoagulation management during subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation is still evolving. OBJECTIVE: The purpose of this study was to assess whether it is safe to perform S-ICD implantation with uninterrupted warfarin. METHODS: This is a single-center retrospective review of patients undergoing S-ICD implantation between October 1, 2012 and June 30, 2017. One hundred thirty-seven patients underwent successful S-ICD implantation during the study period...
November 13, 2017: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/29120016/the-subcutaneous-implantable-cardioverter-defibrillator-in-daily-clinical-practice
#8
Tardu Özkartal, Alexander Breitenstein, Ardan M Saguner, Devdas T Inderbitzin, Markus Wilhelm, Stefano Benussi, Francesco Maisano, Thomas F Lüscher, Frank Ruschitzka, Jan Steffel
INTRODUCTION: In Switzerland, the first implantation of a subcutaneous implantable cardioverter-defibrillator (S-ICD) took place in November 2012. Up until the end of 2016, a total of 111 S-ICDs have been implanted. The aim of this study was to summarise the experience of a tertiary centre in Switzerland and to discuss the results in the context of international registries. METHODS: All patients in whom an S-ICD was implanted between November 2012 and the end of December 2016 at the University Heart Centre Zurich were included in this study...
November 9, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29095967/effects-of-defibrillation-shock-in-patients-implanted-with-a-subcutaneous-defibrillator-a-biomarker-study
#9
Antonio D'Onofrio, Vincenzo Russo, Valter Bianchi, Ciro Cavallaro, Silvia Leonardi, Stefano De Vivo, Filippo Vecchione, Anna Rago, Ernesto Ammendola, Vincenzo Tavoletta, Luigi Atripaldi, Paola Elvira Mocavero, Gerardo Nigro
Aims: Implantable cardioverter defibrillator (ICD) shocks are associated with a subsequent increased risk of death, and an elevation of cardiac enzymes has been measured after defibrillation testing (DFT). In an experimental swine study, subcutaneous ICD (S-ICD) shocks caused less myocardial damage than traditional ICD shocks. The aim of our study was to investigate the association between S-ICD shock and acute cardiac damage in humans, as evaluated by means of sensitive and highly specific circulating biomarkers...
October 31, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/29057442/-subcutaneous-implantable-cardioverter-defibrillator-in-prevention-of-sudden-cardiac-death-in-poland-opinion-paper-endorsed-by-the-polish-cardiac-society-working-group-on-heart-rhythm
#10
Paweł Ptaszyński, Marcin Grabowski, Oskar Kowalski, Maciej Kempa, Przemysław Mitkowski, Andrzej Przybylski, Maciej Sterliński
In the past years, cardiovascular mortality has decreased but despite these cardiovascular diseases are responsible for millions of deaths every year in the world and approximately 25% of which are sudden cardiac death (SCD). Implantable defibrillators (ICD) is proven therapy used in primary and secondary SCD prevention. Currently majority of devices use transvenous leads inserted predominantly into the right heart for both pacing and defibrillation. On the other hand, ICD may cause complica-tions, including inappropriate shocks, device-related infection and lead failure...
2017: Kardiologia Polska
https://www.readbyqxmd.com/read/28978409/specific-indications-and-clinical-outcome-in-patients-with-subcutaneous-icd-a-nationwide-multicentre-registry
#11
Michael Sponder, Cesar Khazen, Wolfgang Dichtl, Lukas Fiedler, Deddo Mörtl, Alexander Teubl, Clemens Steinwender, Martin Martinek, Michael Nürnberg, Daniel Dalos, Johannes Kastner, Christoph Schukro
BACKGROUND: Subcutaneous implantable cardioverter-defibrillators (S-ICD) are an innovative and less invasive alternative to transvenous ICD (TV-ICD) in selected patients. We aimed to investigate the underlying diseases and the specific indications for implanting S-ICD in clinical practice, as well as the prevalence of shock delivery and complications. METHODS AND RESULTS: From December 2012, data of 236 patients (30,5% female; age 48,6±16,8years) were gathered from 12 centres in Austria...
October 1, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28800177/exercise-stress-test-reveals-ineligibility-for-subcutaneous-implantable-cardioverter-defibrillator-in-patients-with-brugada-syndrome
#12
Motomi Tachibana, Nobuhiro Nishii, Hiroshi Morita, Koji Nakagawa, Atsuyuki Watanabe, Kazufumi Nakamura, Hiroshi Ito
BACKGROUND: The eligibility of patients with Brugada syndrome (BrS) for implantation of a subcutaneous implantable cardioverter defibrillator (S-ICD) is not well known. This study aimed to clarify the eligibility of BrS patients for S-ICD using electrocardiography (ECG) at rest and during exercise testing. We also analyzed factors associated with ineligibility for S-ICD from standard 12-lead ECG at rest. METHODS: We enrolled 110 consecutive BrS patients who visited Okayama university hospital from December 2015 to December 2016...
August 11, 2017: Journal of Cardiovascular Electrophysiology
https://www.readbyqxmd.com/read/28797351/implant-and-midterm-outcomes-of-the-subcutaneous-implantable-cardioverter-defibrillator-registry-the-effortless-study
#13
MULTICENTER STUDY
Lucas Boersma, Craig Barr, Reinoud Knops, Dominic Theuns, Lars Eckardt, Petr Neuzil, Marcoen Scholten, Margaret Hood, Juergen Kuschyk, Paul Jones, Elizabeth Duffy, Michael Husby, Kenneth Stein, Pier D Lambiase
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads. The global EFFORTLESS S-ICD (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD) registry is collecting outcomes in 985 patients during a 5-year follow-up. OBJECTIVES: The primary goal of the EFFORTLESS registry is to determine the safety of the S-ICD by evaluating complications and inappropriate shock rate...
August 15, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28765769/initial-experience-with-the-subcutaneous-implantable-cardioverter-defibrillator-in-a-single-japanese-center
#14
Nobuhiro Nishii, Motomi Tachibana, Yoshimasa Morimoto, Satoshi Kawada, Akihito Miyoshi, Hiroyasu Sugiyama, Koji Nakagawa, Atsuyuki Watanabe, Kazufumi Nakamura, Hiroshi Morita, Hiroshi Ito
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is recognized as a viable alternative to the transvenous ICD. The safety and efficacy of this device has been demonstrated in Western countries, but studies with S-ICD implantation in Japanese patients have not been reported. METHODS AND RESULTS: Twelve patients received an S-ICD implant in our institute between February and September 2016. All S-ICDs were successfully implanted without complications...
August 2017: Journal of Arrhythmia
https://www.readbyqxmd.com/read/28754394/a-potentially-lethal-dysfunction-of-a-subcutaneous-implantable-cardiac-defibrillator-the-phantom-menace
#15
Mihaela Calcaianu, Didier Bresson, Jacques Lévy
In this article we describe, to our knowledge, the first case of a potentially lethal dysfunction of a subcutaneous implantable cardioverter-defibrillator (S-ICD). A 70-year-old patient underwent primary S-ICD implantation. Nine months after, communication could not be established with the device. Chest radiography revealed that the lead had moved and wrapped around the generator. After equipment extraction, we observed the lead wound around the sagittal axis of the generator. A burn mark with melted metal was found inside the generator...
August 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28754393/totally-leadless-dual-device-implantation-for-combined-spontaneous-ventricular-tachycardia-defibrillation-and-pacemaker-function-a-first-report
#16
Fozia Zahir Ahmed, Colin Cunnington, Manish Motwani, Amir Masood Zaidi
Subcutaneous implantable cardioverter defibrillators (S-ICDs) provide effective defibrillation, while also reducing the risk of long-term lead problems. However, S-ICDs do not offer bradycardia or antitachycardia pacing and therefore use has been limited. Combined implantation of an S-ICD with a leadless pacemaker (LP) has been proposed to overcome this limitation. Although a handful of combined S-ICD/LP implantations have been reported for Nanostim (St Jude Medical, St Paul, MN) as well as Micra LP (Medtronic, Minneapolis, MN) systems, none have documented delivery of appropriate shock therapies for spontaneous ventricular tachycardia...
August 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28706590/entirely-subcutaneous-defibrillator-and-complex-congenital-heart-disease-data-on-long-term-clinical-follow-up
#17
Paolo Ferrero, Hussam Ali, Palash Barman, Sara Foresti, Pierpaolo Lupo, Emilia D'Elia, Riccardo Cappato, Alan Graham Stuart
AIM: To describe the long-term follow-up of patients with complex congenital heart disease who underwent subcutaneous implantable cardiac defibrillator (S-ICD), focusing on local complications, appropriate and inappropriate shocks. METHODS: Patients with complex congenital heart disease underwent S-ICD implant in two centers with the conventional technique. Data at follow-up were retrieved from clinical notes and institutional database. RESULTS: Eight patients were implanted in two centres between 2010 and 2016...
June 26, 2017: World Journal of Cardiology
https://www.readbyqxmd.com/read/28687562/efficacy-and-safety-of-the-subcutaneous-implantable-cardioverter-defibrillator-a-systematic-review
#18
REVIEW
Colin Dominic Chue, Chun Shing Kwok, Chun Wai Wong, Ashish Patwala, Diane Barker, Amir Zaidi, Mamas A Mamas, Colin Cunnington, Fozia Z Ahmed
BACKGROUND: Subcutaneous implantable cardioverter defibrillators (S-ICDs) are considered an alternative to conventional transvenous ICDs (TV-ICDs) in patients not requiring pacing. METHODS: We searched MEDLINE and EMBASE for studies evaluating efficacy and safety outcomes in S-ICD patients. Outcomes were pooled across studies. RESULTS: Sixteen studies were included with 5380 participants (mean age range 33-56 years). Short-term follow-up data were available for 1670 subjects...
September 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28625372/multicenter-automatic-defibrillator-implantation-trial-subcutaneous-implantable-cardioverter-defibrillator-madit-s-icd-design-and-clinical-protocol
#19
RANDOMIZED CONTROLLED TRIAL
Valentina Kutyifa, Christopher Beck, Mary W Brown, David Cannom, James Daubert, Mark Estes, Henry Greenberg, Ilan Goldenberg, Stephen Hammes, David Huang, Helmut Klein, Reinoud Knops, Mikhail Kosiborod, Jeanne Poole, Claudio Schuger, Jagmeet P Singh, Scott Solomon, David Wilber, Wojciech Zareba, Arthur J Moss
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator...
July 2017: American Heart Journal
https://www.readbyqxmd.com/read/28624663/role-of-exercise-electrocardiogram-to-screen-for-t-wave-oversensing-after-implantation-of-subcutaneous-implantable-cardioverter-defibrillator
#20
Muhammad R Afzal, Christopher Evenson, Auroa Badin, Dilesh Patel, Hemant Godara, Michael Essandoh, Toshimasa Okabe, Jaret Tyler, Mahmoud Houmsse, Ralph Augostini, John Hummel, Steven Kalbfleisch, Emile G Daoud, Raul Weiss
BACKGROUND: During early experience with subcutaneous implantable cardioverter-defibrillators (S-ICD), several patients had inappropriate shocks from T-wave oversensing (TWOS) during exercise. This prompted some operators to perform routine treadmill exercise tests after implantation of S-ICD to screen for TWOS. Meanwhile, improvements have been made in the detection algorithms by the manufacturer. OBJECTIVE: To assess whether routine treadmill exercise post S-ICD implantation is warranted...
October 2017: Heart Rhythm: the Official Journal of the Heart Rhythm Society
keyword
keyword
111377
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"